Eli Lilly and Company and AstraZeneca announced the start of recruitment of patients for the Phase II/III AMARANTH clinical trial of an inhibitor of beta secretes cleaving enzyme (BACE), currently under development as a promising therapy for Alzheimer’s disease.

The AMARANTH Phase II/III clinical trial will evaluate the safety and efficacy of oral AZD3293/LY3314814 against placebo and will assess if this drug can be designated as disease-modifying therapy for patients with early Alzheimer’s disease. The state of early Alzheimer’s disease includes patients with mild cognitive impairment (MCI) associated with Alzheimer’s disease and patients with mild Alzheimer’s dementia. This new study will include more than 1,500 patients in 15 countries, and the treatment will be for 2 years.

Source:  Alzheimer’s News Today

Links

Alzheimer's News Today Link